Medpace (MEDP) Stock Price, News & Analysis

Company Overview

Medpace Holdings, Inc. is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services. Medpace focuses on a range of therapeutic areas, including oncology, cardiovascular disease, metabolic disorders, neurology, rare and orphan diseases, and infectious diseases.

Founded in 1992, Medpace is headquartered in Cincinnati, Ohio, and conducts studies across North America, Europe, Latin America and the Asia-Pacific region. The company was founded by August J. Troendle, who serves as its chairman and chief executive officer.

Key Stats

• Today's Range: $613.10 to $627.04
• 50-Day Range: $527.93 to $624.20
• 52-Week Range: $373.00 to $677.90
• Volume: 185,380 shs
• Average Volume: 209,977 shs
• Market Capitalization: $17.42 billion
• P/E Ratio: 36.59
• Dividend Yield: N/A
• Price Target: $595.20
• Consensus Rating: Hold

Medpace Stock Analysis - MarketRank™

Medpace scored higher than 49% of companies evaluated by MarketBeat, and ranked 496th out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Hold

Consensus Rating

Medpace has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 3 buy ratings, 9 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Medpace is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Medpace has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 9.29%

Earnings Growth

Earnings for Medpace are expected to grow by 9.29% in the coming year, from $17.54 to $19.17 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Medpace is 36.59, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.04.

Price to Earnings Ratio vs. Sector

The P/E ratio of Medpace is 36.59, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.10.

Price to Earnings Growth Ratio

Medpace has a PEG Ratio of 2.73. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Medpace has a P/B Ratio of 38.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.53% of the float of Medpace has been sold short.

Short Interest Ratio / Days to Cover

Medpace has a short interest ratio ("days to cover") of 8.22.

Change versus previous month

Short interest in Medpace has recently increased by 5.83%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Medpace does not currently pay a dividend.

Dividend Growth

Medpace does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.71

News Sentiment

Medpace has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Medpace this week, compared to 9 articles on an average week.

Search Interest

Only 1 people have searched for MEDP on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

Only 8 people have added Medpace to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Medpace insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $104,265,412.00 in company stock.

Percentage Held by Insiders

20.50% of the stock of Medpace is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

77.98% of the stock of Medpace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/22/2026
• Today: 9/22/2026
• Next Earnings (Estimated): 10/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:MEDP
• CIK: 1668397
• Web: www.medpace.com
• Phone: (513) 579-9911
• Fax: 513-579-0444
• Employees: 6,200
• Year Founded: 1992

Price Target and Rating

• Average Price Target for Medpace: $595.20
• High Price Target: $692.00
• Low Price Target: $492.00
• Potential Upside/Downside: -4.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): $17.06
• Trailing P/E Ratio: 36.59
• Forward P/E Ratio: 35.59
• P/E Growth: 2.73
• Net Income: $451.12 million
• Net Margins: 17.67%
• Pretax Margin: 21.53%
• Return on Equity: 110.15%
• Return on Assets: 24.84%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.73
• Quick Ratio: 0.73

Sales & Book Value

• Annual Sales: $2.53 billion
• Price / Sales: 6.89
• Cash Flow: $17.34 per share
• Price / Cash Flow: 35.99
• Book Value: $16.30 per share
• Price / Book: 38.29

Miscellaneous

• Outstanding Shares: 27,910,000
• Free Float: 22,190,000
• Market Cap: $17.42 billion
• Optionable: Optionable
• Beta: 1.15